Last 12 months
Inside the activity.
0 purchase rows · 83 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 9 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 17 |
| Apr 2026 | 0 | 8 |
| May 2026 | 0 | 9 |
| Jun 2026 | 0 | 8 |
| Jul 2026 | 0 | 9 |
| Aug 2026 | 0 | 4 |
| Sep 2026 | 0 | 8 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2020 Filed Mar 3, 2020 18:44 UTC |
Malik Fady IbrahamEVP Research & Development
|
Tax withholdingCommon Stock | 2,075 | $13.94 | $28,925.50 |
DisclosureSEC source: 0001061983-20-000050 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,621 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 02/28/2020 and does not represent a sale by the reporting person. F2 · balance_after: Includes up to 5,135 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 23:19 UTC |
Malik Fady IbrahamEVP Research & Development
|
Tax withholdingCommon Stock | 5,533 | $13.94 | $77,130.02 |
DisclosureSEC source: 0001061983-20-000046 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,696 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 02/27/2020 and does not represent a sale by the reporting person. F2 · balance_after: Includes up to 5,135 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 23:19 UTC |
Blum Robert IDirector · President & CEO
|
Tax withholdingCommon Stock | 13,832 | $13.94 | $192,818.08 |
DisclosureSEC source: 0001061983-20-000045 · edgardoc.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,594 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 02/27/2020 and does not represent a sale by the reporting person. F2 · balance_after: Includes up to 8,846 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 23:18 UTC |
Cragg DavidSVP Human Resources
|
Tax withholdingCommon Stock | 4,150 | $13.94 | $57,851.00 |
DisclosureSEC source: 0001061983-20-000044 · edgardoc.xml · nonDerivative · entry 1 Cragg David · CIK 0001316459 · SVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,482 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 02/27/2020 and does not represent a sale by the reporting person. F2 · balance_after: Includes up to 11,616 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 23:18 UTC |
Jaw ChingSVP Finance & CFO
|
Tax withholdingCommon Stock | 2,767 | $13.94 | $38,571.98 |
DisclosureSEC source: 0001061983-20-000043 · edgardoc.xml · nonDerivative · entry 1 Jaw Ching · CIK 0001710875 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,165 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 02/27/2020 and does not represent a sale by the reporting person. F2 · balance_after: Includes up to 513 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 19:49 UTC |
Blum Robert IDirector · President & CEO
|
Tax withholdingCommon Stock | 16,681 | $14.07 | $234,618.27 |
DisclosureSEC source: 0001061983-20-000035 · edgardoc.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,426 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 02/26/2020 and does not represent a sale by the reporting person. F2 · balance_after: Includes up to 8,846 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 20:39 UTC |
Malik Fady IbrahamEVP Research & Development
|
Tax withholdingCommon Stock | 7,121 | $14.07 | $100,156.87 |
DisclosureSEC source: 0001061983-20-000038 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,229 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 02/26/2020 and does not represent a sale by the reporting person. F2 · balance_after: Includes up to 5,135 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 20:39 UTC |
Jaw ChingSVP Finance & CFO
|
Tax withholdingCommon Stock | 4,399 | $14.07 | $61,871.94 |
DisclosureSEC source: 0001061983-20-000037 · edgardoc.xml · nonDerivative · entry 1 Jaw Ching · CIK 0001710875 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,932 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 02/26/2020 and does not represent a sale by the reporting person. F2 · balance_after: Includes up to 513 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 20:38 UTC |
Cragg DavidSVP Human Resources
|
Tax withholdingCommon Stock | 4,431 | $14.07 | $62,322.02 |
DisclosureSEC source: 0001061983-20-000036 · edgardoc.xml · nonDerivative · entry 1 Cragg David · CIK 0001316459 · SVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,632 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 02/26/2020 and does not represent a sale by the reporting person. F2 · balance_after: Includes up to 11,616 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 23:00 UTC |
BVF PARTNERS L P/IL10% owner
BIOTECHNOLOGY VALUE FUND L PSee Explanation of Responses
BIOTECHNOLOGY VALUE FUND II LPSee Explanation of Responses
Biotechnology Value Trading Fund OS LPSee Explanation of Responses
BVF Partners OS Ltd.See Explanation of Responses
BVF INC/IL10% owner
LAMPERT MARK N10% owner
|
SaleCommon Stock, $0.001 par value | 74,893 | $15.79 | $1,182,320.81 |
DisclosureSEC source: 0000921895-20-000588 · form407422010_02182020.xml · nonDerivative · entry 3 BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses BVF INC/IL · CIK 0001056807 · 10% owner LAMPERT MARK N · CIK 0001233840 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,419 F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Following the transactions reported herein, for the purposes of Section 16, the Reporting Persons ceased to beneficially own 10% or more of the outstanding shares of Common Stock of the Issuer. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. F4 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 23:00 UTC |
BVF PARTNERS L P/IL10% owner
BIOTECHNOLOGY VALUE FUND L PSee Explanation of Responses
BIOTECHNOLOGY VALUE FUND II LPSee Explanation of Responses
Biotechnology Value Trading Fund OS LPSee Explanation of Responses
BVF Partners OS Ltd.See Explanation of Responses
BVF INC/IL10% owner
LAMPERT MARK N10% owner
|
SaleCommon Stock, $0.001 par value | 510,793 | $15.79 | $8,063,786.93 |
DisclosureSEC source: 0000921895-20-000588 · form407422010_02182020.xml · nonDerivative · entry 2 BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses BVF INC/IL · CIK 0001056807 · 10% owner LAMPERT MARK N · CIK 0001233840 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,350,829 F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Following the transactions reported herein, for the purposes of Section 16, the Reporting Persons ceased to beneficially own 10% or more of the outstanding shares of Common Stock of the Issuer. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. F3 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 23:00 UTC |
BVF PARTNERS L P/IL10% owner
BIOTECHNOLOGY VALUE FUND L PSee Explanation of Responses
BIOTECHNOLOGY VALUE FUND II LPSee Explanation of Responses
Biotechnology Value Trading Fund OS LPSee Explanation of Responses
BVF Partners OS Ltd.See Explanation of Responses
BVF INC/IL10% owner
LAMPERT MARK N10% owner
|
SaleCommon Stock, $0.001 par value | 486,344 | $15.79 | $7,677,815.46 |
DisclosureSEC source: 0000921895-20-000588 · form407422010_02182020.xml · nonDerivative · entry 1 BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses BVF INC/IL · CIK 0001056807 · 10% owner LAMPERT MARK N · CIK 0001233840 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,131,432 F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Following the transactions reported herein, for the purposes of Section 16, the Reporting Persons ceased to beneficially own 10% or more of the outstanding shares of Common Stock of the Issuer. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. F2 · ownership.direct: Securities owned directly by BVF. As the general partner of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 22:39 UTC |
Califf RobertDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,957 | $15.43 Strike: $15.43 | $91,916.51 |
DisclosureSEC source: 0001061983-20-000029 · edgardoc.xml · derivative · entry 1 Califf Robert · CIK 0001574557 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,957 Underlying: Common Stock · 5,957 shares Expires 2030-02-12 Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 22:40 UTC |
PARSHALL B LYNNEDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,749 | $15.43 Strike: $15.43 | $42,417.07 |
DisclosureSEC source: 0001061983-20-000032 · edgardoc.xml · derivative · entry 1 PARSHALL B LYNNE · CIK 0001073385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,749 Underlying: Common Stock · 2,749 shares Expires 2030-02-12 Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 22:40 UTC |
SMITH SANDFORD DDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,124 | $15.43 Strike: $15.43 | $63,633.32 |
DisclosureSEC source: 0001061983-20-000033 · edgardoc.xml · derivative · entry 1 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,124 Underlying: Common Stock · 4,124 shares Expires 2030-02-12 Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 22:40 UTC |
Kaye Edward M. MDDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 8,248 | $15.43 Strike: $15.43 | $127,266.64 |
DisclosureSEC source: 0001061983-20-000031 · edgardoc.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,248 Underlying: Common Stock · 8,248 shares Expires 2030-02-12 Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 22:39 UTC |
HENDERSON JOHN TDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 6,415 | $15.43 Strike: $15.43 | $98,983.45 |
DisclosureSEC source: 0001061983-20-000030 · edgardoc.xml · derivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,415 Underlying: Common Stock · 6,415 shares Expires 2030-02-12 Read SEC document |
| January 15, 2020 Filed Jan 16, 2020 21:53 UTC |
Blum Robert IDirector · President & CEO
|
SaleCommon Stock | 4,950 | $12.96 | $64,158.93 |
DisclosureSEC source: 0001061983-20-000015 · edgardoc.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,107 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 23:55 UTC |
Califf RobertDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 758 | $10.55 Strike: $10.55 | $7,996.90 |
DisclosureSEC source: 0001061983-20-000013 · edgardoc.xml · derivative · entry 1 Califf Robert · CIK 0001574557 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 758 Underlying: Common Stock · 758 shares Expires 2030-01-02 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on January 2, 2021. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 23:55 UTC |
HENDERSON JOHN TDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,517 | $10.55 Strike: $10.55 | $16,004.35 |
DisclosureSEC source: 0001061983-20-000012 · edgardoc.xml · derivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,517 Underlying: Common Stock · 1,517 shares Expires 2030-01-02 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on January 2, 2021. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 23:52 UTC |
SMITH SANDFORD DDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 758 | $10.55 Strike: $10.55 | $7,996.90 |
DisclosureSEC source: 0001061983-20-000007 · edgardoc.xml · derivative · entry 1 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 758 Underlying: Common Stock · 758 shares Expires 2030-01-02 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on January 2, 2021. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 23:55 UTC |
Kaye Edward M. MDDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,517 | $10.55 Strike: $10.55 | $16,004.35 |
DisclosureSEC source: 0001061983-20-000011 · edgardoc.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,517 Underlying: Common Stock · 1,517 shares Expires 2030-01-02 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on January 2, 2021. Read SEC document |
| January 02, 2020 Filed Jan 29, 2020 17:58 UTC Amendment |
Califf RobertDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,739 | $10.55 Strike: $10.55 | $49,996.45 |
DisclosureSEC source: 0001061983-20-000023 · edgardoc.xml · derivative · entry 1 Califf Robert · CIK 0001574557 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,739 Underlying: Common Stock · 4,739 shares Expires 2030-01-02 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on January 2, 2021. F2 · derivative.underlying_shares: This Form 4/A is being filed to report the correct number of shares underlying the stock option, which was granted to the reporting person in connection with his election to receive 50% of his non-employee director retainer in equity, pursuant to the methodology described in the Company's most recent Proxy Statement. The number of shares reported on the Form 4 filed January 6, 2020 was incorrect due to an administrative error. Read SEC document |
| January 02, 2020 Filed Jan 29, 2020 17:57 UTC Amendment |
Kaye Edward M. MDDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 9,479 | $10.55 Strike: $10.55 | $100,003.45 |
DisclosureSEC source: 0001061983-20-000021 · edgardoc.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,479 Underlying: Common Stock · 9,479 shares Expires 2030-01-02 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on January 2, 2021. F2 · derivative.underlying_shares: This Form 4/A is being filed to report the correct number of shares underlying the stock option, which was granted to the reporting person in connection with his election to receive 100% of his non-employee director retainer in equity, pursuant to the methodology described in the Company's most recent Proxy Statement. The number of shares reported on the Form 4 filed January 6, 2020 was incorrect due to an administrative error. Read SEC document |
| January 02, 2020 Filed Jan 29, 2020 17:57 UTC Amendment |
HENDERSON JOHN TDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 9,479 | $10.55 Strike: $10.55 | $100,003.45 |
DisclosureSEC source: 0001061983-20-000022 · edgardoc.xml · derivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,479 Underlying: Common Stock · 9,479 shares Expires 2030-01-02 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on January 2, 2021. F2 · derivative.underlying_shares: This Form 4/A is being filed to report the correct number of shares underlying the stock option, which was granted to the reporting person in connection with his election to receive 100% of his non-employee director retainer in equity, pursuant to the methodology described in the Company's most recent Proxy Statement. The number of shares reported on the Form 4 filed January 6, 2020 was incorrect due to an administrative error. Read SEC document |
| January 02, 2020 Filed Jan 29, 2020 17:54 UTC Amendment |
SMITH SANDFORD DDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,739 | $10.55 Strike: $10.55 | $49,996.45 |
DisclosureSEC source: 0001061983-20-000020 · edgardoc.xml · derivative · entry 1 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,739 Underlying: Common Stock · 4,739 shares Expires 2030-01-02 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on January 2, 2021. F2 · derivative.underlying_shares: This Form 4/A is being filed to report the correct number of shares underlying the stock option, which was granted to the reporting person in connection with his election to receive 50% of his non-employee director retainer in equity, pursuant to the methodology described in the Company's most recent Proxy Statement. The number of shares reported on the Form 4 filed January 6, 2020 was incorrect due to an administrative error. Read SEC document |
| December 16, 2019 Filed Dec 17, 2019 21:24 UTC |
Blum Robert IDirector · President & CEO
|
SaleCommon Stock | 6,000 | $10.22 | $61,326.00 |
DisclosureSEC source: 0001061983-19-000073 · edgardoc.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,057 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 00:49 UTC |
BVF PARTNERS L P/IL10% owner
BIOTECHNOLOGY VALUE FUND L PSee Explanation of Responses
BIOTECHNOLOGY VALUE FUND II LPSee Explanation of Responses
Biotechnology Value Trading Fund OS LPSee Explanation of Responses
BVF Partners OS Ltd.See Explanation of Responses
BVF INC/IL10% owner
LAMPERT MARK N10% owner
|
PurchaseCommon Stock, $0.001 par value | 8,506 | $9.52 | $80,934.59 |
DisclosureSEC source: 0000921895-19-002981 · form407422010_12122019.xml · nonDerivative · entry 6 BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses BVF INC/IL · CIK 0001056807 · 10% owner LAMPERT MARK N · CIK 0001233840 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 499,312 F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. F4 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 00:49 UTC |
BVF PARTNERS L P/IL10% owner
BIOTECHNOLOGY VALUE FUND L PSee Explanation of Responses
BIOTECHNOLOGY VALUE FUND II LPSee Explanation of Responses
Biotechnology Value Trading Fund OS LPSee Explanation of Responses
BVF Partners OS Ltd.See Explanation of Responses
BVF INC/IL10% owner
LAMPERT MARK N10% owner
|
PurchaseCommon Stock, $0.001 par value | 49,804 | $9.52 | $473,885.06 |
DisclosureSEC source: 0000921895-19-002981 · form407422010_12122019.xml · nonDerivative · entry 5 BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses BVF INC/IL · CIK 0001056807 · 10% owner LAMPERT MARK N · CIK 0001233840 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,861,622 F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. F3 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 00:49 UTC |
BVF PARTNERS L P/IL10% owner
BIOTECHNOLOGY VALUE FUND L PSee Explanation of Responses
BIOTECHNOLOGY VALUE FUND II LPSee Explanation of Responses
Biotechnology Value Trading Fund OS LPSee Explanation of Responses
BVF Partners OS Ltd.See Explanation of Responses
BVF INC/IL10% owner
LAMPERT MARK N10% owner
|
PurchaseCommon Stock, $0.001 par value | 60,103 | $9.52 | $571,880.05 |
DisclosureSEC source: 0000921895-19-002981 · form407422010_12122019.xml · nonDerivative · entry 4 BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses BVF INC/IL · CIK 0001056807 · 10% owner LAMPERT MARK N · CIK 0001233840 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,617,776 F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. F2 · ownership.direct: Securities owned directly by BVF. As the general partner of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF. Read SEC document |
| December 10, 2019 Filed Dec 13, 2019 00:49 UTC |
BVF PARTNERS L P/IL10% owner
BIOTECHNOLOGY VALUE FUND L PSee Explanation of Responses
BIOTECHNOLOGY VALUE FUND II LPSee Explanation of Responses
Biotechnology Value Trading Fund OS LPSee Explanation of Responses
BVF Partners OS Ltd.See Explanation of Responses
BVF INC/IL10% owner
LAMPERT MARK N10% owner
|
PurchaseCommon Stock, $0.001 par value | 15,030 | $9.40 | $141,282.00 |
DisclosureSEC source: 0000921895-19-002981 · form407422010_12122019.xml · nonDerivative · entry 3 BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses BVF INC/IL · CIK 0001056807 · 10% owner LAMPERT MARK N · CIK 0001233840 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 490,806 F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. F4 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS. Read SEC document |
| December 10, 2019 Filed Dec 13, 2019 00:49 UTC |
BVF PARTNERS L P/IL10% owner
BIOTECHNOLOGY VALUE FUND L PSee Explanation of Responses
BIOTECHNOLOGY VALUE FUND II LPSee Explanation of Responses
Biotechnology Value Trading Fund OS LPSee Explanation of Responses
BVF Partners OS Ltd.See Explanation of Responses
BVF INC/IL10% owner
LAMPERT MARK N10% owner
|
PurchaseCommon Stock, $0.001 par value | 95,100 | $9.40 | $893,940.00 |
DisclosureSEC source: 0000921895-19-002981 · form407422010_12122019.xml · nonDerivative · entry 2 BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses BVF INC/IL · CIK 0001056807 · 10% owner LAMPERT MARK N · CIK 0001233840 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,811,818 F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. F3 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2. Read SEC document |
| December 10, 2019 Filed Dec 13, 2019 00:49 UTC |
BVF PARTNERS L P/IL10% owner
BIOTECHNOLOGY VALUE FUND L PSee Explanation of Responses
BIOTECHNOLOGY VALUE FUND II LPSee Explanation of Responses
Biotechnology Value Trading Fund OS LPSee Explanation of Responses
BVF Partners OS Ltd.See Explanation of Responses
BVF INC/IL10% owner
LAMPERT MARK N10% owner
|
PurchaseCommon Stock, $0.001 par value | 113,529 | $9.40 | $1,067,172.60 |
DisclosureSEC source: 0000921895-19-002981 · form407422010_12122019.xml · nonDerivative · entry 1 BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses BVF INC/IL · CIK 0001056807 · 10% owner LAMPERT MARK N · CIK 0001233840 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,557,673 F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. F2 · ownership.direct: Securities owned directly by BVF. As the general partner of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF. Read SEC document |
| December 05, 2019 Filed Dec 6, 2019 21:42 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 1,500 | $9.80 | $14,700.00 |
DisclosureSEC source: 0001061983-19-000071 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,350 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2018. Read SEC document |
| November 19, 2019 Filed Jan 2, 2020 19:22 UTC |
HENDERSON JOHN TDirector
|
PurchaseCommon Stock | 6,000 | $8.57 | $51,426.60 |
DisclosureSEC source: 0001061983-20-000005 · edgardoc.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 21:12 UTC |
Blum Robert IDirector · President & CEO
|
SaleCommon Stock | 6,000 | $8.08 | $48,508.20 |
DisclosureSEC source: 0001061983-19-000067 · edgardoc.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,057 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. Read SEC document |
| November 07, 2019 Filed Nov 8, 2019 22:08 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 1,500 | $9.98 | $14,970.00 |
DisclosureSEC source: 0001061983-19-000065 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,850 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2018. Read SEC document |
| October 15, 2019 Filed Oct 16, 2019 21:42 UTC |
Blum Robert IDirector · President & CEO
|
SaleCommon Stock | 6,000 | $11.16 | $66,975.00 |
DisclosureSEC source: 0001061983-19-000063 · edgardoc.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,022 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. Read SEC document |
| October 03, 2019 Filed Oct 4, 2019 21:13 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 1,500 | $11.22 | $16,830.00 |
DisclosureSEC source: 0001061983-19-000061 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,067 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2018. Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 21:08 UTC |
Blum Robert IDirector · President & CEO
|
SaleCommon Stock | 6,000 | $12.74 | $76,469.40 |
DisclosureSEC source: 0001061983-19-000059 · edgardoc.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,022 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. Read SEC document |
| September 05, 2019 Filed Sep 6, 2019 20:48 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 1,500 | $13.69 | $20,531.25 |
DisclosureSEC source: 0001061983-19-000057 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,567 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2018. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 21:45 UTC |
Blum Robert IDirector · President & CEO
|
SaleCommon Stock | 6,000 | $12.64 | $75,814.80 |
DisclosureSEC source: 0001061983-19-000055 · edgardoc.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,022 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 21:07 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 1,500 | $13.52 | $20,280.00 |
DisclosureSEC source: 0001061983-19-000053 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,067 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2018. Read SEC document |
| July 15, 2019 Filed Jul 16, 2019 21:25 UTC |
Blum Robert IDirector · President & CEO
|
SaleCommon Stock | 6,000 | $10.94 | $65,632.20 |
DisclosureSEC source: 0001061983-19-000050 · edgardoc.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,022 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. Read SEC document |
| July 11, 2019 Filed Jul 12, 2019 23:41 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 1,500 | $11.26 | $16,890.00 |
DisclosureSEC source: 0001061983-19-000048 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,567 Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 20:52 UTC |
Blum Robert IDirector · President & CEO
|
SaleCommon Stock | 6,000 | $9.71 | $58,238.40 |
DisclosureSEC source: 0001061983-19-000046 · edgardoc.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,022 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 21:37 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 1,500 | $10.31 | $15,462.75 |
DisclosureSEC source: 0001061983-19-000044 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,067 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2018. Read SEC document |
| May 22, 2019 Filed Mar 20, 2020 19:21 UTC |
GAGE L PATRICKDirector
|
GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-20-000068 · edgardoc.xml · nonDerivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 F1 · kind: Bona Fide Gift Read SEC document |
| May 15, 2019 Filed May 17, 2019 17:07 UTC |
COSTA SANTO JDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $10.68 Strike: $10.68 | $213,600.00 |
DisclosureSEC source: 0001061983-19-000034 · edgardoc.xml · derivative · entry 1 COSTA SANTO J · CIK 0001013419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-05-15 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on May 15, 2020 Read SEC document |
| May 15, 2019 Filed May 17, 2019 21:07 UTC |
HENDERSON JOHN TDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $10.68 Strike: $10.68 | $213,600.00 |
DisclosureSEC source: 0001061983-19-000036 · edgardoc.xml · derivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-05-15 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on May 15, 2020 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.